AbbVie is one of the largest global Pharmaceuticals, with a market cap of >$265bn. The company's lead asset - all-time best selling immunology drug Humira - finally loses patent protection this year ...

FILE - Packaging for AbbVie's drug, Humira. Patients who take the autoimmune disease treatment can get some price relief when lower-cost, biosimilar versions are included on health plan formularies.

Evio Pharmacy Solutions, the for-profit pharmacy solutions company formed by five Blue Cross & Blue Shield licensees, said today it has entered a unique direct-purchase deal for a cheaper version of ...

Sales of AbbVie’s blockbuster drug Humira peaked at $18.9bn last year and, according to analysts at Evaluate Pharma, the product is expected to generate $15.2bn through to 2024. These figures are ...

Tennessee last year spent $48 million on a single drug, Humira — about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment. So ...

Please provide your email address to receive an email when new articles are posted on . AbbVie reported a worldwide net revenue of $12.31 billion and a 0.7% increase in its first quarter. Global net ...

HUMIRA can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. HUMIRA has been shown to reduce the rate of progression of joint damage as ...

Otezla (apremilast) and Humira (adalimumab) are prescription drugs used to treat plaque psoriasis and psoriatic arthritis in adults. Otezla comes as an oral tablet, and Humira comes as a liquid ...

You might call it the Swiss army knife of pharmaceutical drugs. Since it hit the market in 2002 to treat rheumatoid arthritis, Humira has racked up one governmental approval after another to treat ...